Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Identifieur interne : 002834 ( Main/Exploration ); précédent : 002833; suivant : 002835Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Auteurs : K Rajender Reddy [États-Unis] ; Stefan Zeuzem [Allemagne] ; Fabien Zoulim [France] ; Ola Weiland [Suède] ; Andrzej Horban [Pologne] ; Carol Stanciu [Roumanie] ; Federico Guillermo Villamil [Argentine] ; Pietro Andreone [Italie] ; Jacob George [Australie] ; Elisabeth Dammers [Belgique] ; Min Fu [États-Unis] ; Darryl Kurland [États-Unis] ; Oliver Lenz [Belgique] ; Sivi Ouwerkerk-Mahadevan [Belgique] ; Thierry Verbinnen [Belgique] ; Jane Scott [Royaume-Uni] ; Wolfgang Jessner [Belgique]Source :
- The Lancet. Infectious diseases [ 1474-4457 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antiviraux (usage thérapeutique), Composés hétérocycliques 3 noyaux (usage thérapeutique), Femelle, Génotype, Hepacivirus (), Hepacivirus (génétique), Hepacivirus (isolement et purification), Humains, Hépatite C chronique (traitement médicamenteux), Hépatite C chronique (virologie), Interféron alpha (usage thérapeutique), Jeune adulte, Mâle, Méthode en double aveugle, Oligopeptides (usage thérapeutique), Placebo (administration et posologie), Polyéthylène glycols (usage thérapeutique), Protéines recombinantes (usage thérapeutique), Ribavirine (usage thérapeutique), Résultat thérapeutique, Siméprévir, Sujet âgé, Sulfonamides (usage thérapeutique).
- MESH :
- administration et posologie : Placebo.
- génétique : Hepacivirus.
- isolement et purification : Hepacivirus.
- traitement médicamenteux : Hépatite C chronique.
- usage thérapeutique : Antiviraux, Composés hétérocycliques 3 noyaux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine, Sulfonamides.
- virologie : Hépatite C chronique.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Génotype, Hepacivirus, Humains, Jeune adulte, Mâle, Méthode en double aveugle, Résultat thérapeutique, Siméprévir, Sujet âgé.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antiviral Agents (therapeutic use), Double-Blind Method, Female, Genotype, Hepacivirus (classification), Hepacivirus (genetics), Hepacivirus (isolation & purification), Hepatitis C, Chronic (drug therapy), Hepatitis C, Chronic (virology), Heterocyclic Compounds, 3-Ring (therapeutic use), Humans, Interferon-alpha (therapeutic use), Male, Middle Aged, Oligopeptides (therapeutic use), Placebos (administration & dosage), Polyethylene Glycols (therapeutic use), Recombinant Proteins (therapeutic use), Ribavirin (therapeutic use), Simeprevir, Sulfonamides (therapeutic use), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Placebos.
- chemical , therapeutic use : Antiviral Agents, Heterocyclic Compounds, 3-Ring, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin, Sulfonamides.
- classification : Hepacivirus.
- drug therapy : Hepatitis C, Chronic.
- genetics : Hepacivirus.
- isolation & purification : Hepacivirus.
- virology : Hepatitis C, Chronic.
- Adolescent, Adult, Aged, Double-Blind Method, Female, Genotype, Humans, Male, Middle Aged, Simeprevir, Treatment Outcome, Young Adult.
Abstract
We did a phase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and compensated liver disease that related to the standard of care for these patients at the time this study was initiated. We investigated whether simeprevir is non-inferior in terms of efficacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin.
DOI: 10.1016/S1473-3099(14)71002-3
PubMed: 25482330
Affiliations:
- Allemagne, Argentine, Australie, Belgique, France, Italie, Pologne, Roumanie, Royaume-Uni, Suède, États-Unis
- Auvergne-Rhône-Alpes, District de Darmstadt, Hesse (Land), New Jersey, Pennsylvanie, Rhône-Alpes, Svealand
- Francfort-sur-le-Main, Lyon, Stockholm
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003121
- to stream PubMed, to step Curation: 003025
- to stream PubMed, to step Checkpoint: 003025
- to stream Ncbi, to step Merge: 002079
- to stream Ncbi, to step Curation: 002079
- to stream Ncbi, to step Checkpoint: 002079
- to stream Main, to step Merge: 002834
- to stream Main, to step Curation: 002834
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.</title><author><name sortKey="Reddy, K Rajender" sort="Reddy, K Rajender" uniqKey="Reddy K" first="K Rajender" last="Reddy">K Rajender Reddy</name><affiliation wicri:level="2"><nlm:affiliation>Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: rajender.reddy@uphs.upenn.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, JW Goethe University Hospital, Frankfurt, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medicine, JW Goethe University Hospital, Frankfurt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name><affiliation wicri:level="3"><nlm:affiliation>Hospices Civils de Lyon, INSERM U1052, Lyon 1 University, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospices Civils de Lyon, INSERM U1052, Lyon 1 University, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Weiland, Ola" sort="Weiland, Ola" uniqKey="Weiland O" first="Ola" last="Weiland">Ola Weiland</name><affiliation wicri:level="3"><nlm:affiliation>Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Horban, Andrzej" sort="Horban, Andrzej" uniqKey="Horban A" first="Andrzej" last="Horban">Andrzej Horban</name><affiliation wicri:level="1"><nlm:affiliation>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Stanciu, Carol" sort="Stanciu, Carol" uniqKey="Stanciu C" first="Carol" last="Stanciu">Carol Stanciu</name><affiliation wicri:level="1"><nlm:affiliation>Gastromedica Clinic, University Hospital St Spiridon, Iasi, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Gastromedica Clinic, University Hospital St Spiridon, Iasi</wicri:regionArea><wicri:noRegion>Iasi</wicri:noRegion></affiliation></author><author><name sortKey="Villamil, Federico Guillermo" sort="Villamil, Federico Guillermo" uniqKey="Villamil F" first="Federico Guillermo" last="Villamil">Federico Guillermo Villamil</name><affiliation wicri:level="1"><nlm:affiliation>CIPREC, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>CIPREC, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Andreone, Pietro" sort="Andreone, Pietro" uniqKey="Andreone P" first="Pietro" last="Andreone">Pietro Andreone</name><affiliation wicri:level="1"><nlm:affiliation>Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna and AOU Policlinico Sant'Orsola-Malpighi, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna and AOU Policlinico Sant'Orsola-Malpighi, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="George, Jacob" sort="George, Jacob" uniqKey="George J" first="Jacob" last="George">Jacob George</name><affiliation wicri:level="1"><nlm:affiliation>Storr Liver Unit, Westmead Hospital and Westmead Millennium Institute, Westmead, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Storr Liver Unit, Westmead Hospital and Westmead Millennium Institute, Westmead, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Dammers, Elisabeth" sort="Dammers, Elisabeth" uniqKey="Dammers E" first="Elisabeth" last="Dammers">Elisabeth Dammers</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Fu, Min" sort="Fu, Min" uniqKey="Fu M" first="Min" last="Fu">Min Fu</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research and Development, Spring House, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research and Development, Spring House, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Kurland, Darryl" sort="Kurland, Darryl" uniqKey="Kurland D" first="Darryl" last="Kurland">Darryl Kurland</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research and Development, Titusville, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research and Development, Titusville, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Ouwerkerk Mahadevan, Sivi" sort="Ouwerkerk Mahadevan, Sivi" uniqKey="Ouwerkerk Mahadevan S" first="Sivi" last="Ouwerkerk-Mahadevan">Sivi Ouwerkerk-Mahadevan</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Research and Development, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Research and Development, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Verbinnen, Thierry" sort="Verbinnen, Thierry" uniqKey="Verbinnen T" first="Thierry" last="Verbinnen">Thierry Verbinnen</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Scott, Jane" sort="Scott, Jane" uniqKey="Scott J" first="Jane" last="Scott">Jane Scott</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Global Services, High Wycombe, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Janssen Global Services, High Wycombe</wicri:regionArea><wicri:noRegion>High Wycombe</wicri:noRegion></affiliation></author><author><name sortKey="Jessner, Wolfgang" sort="Jessner, Wolfgang" uniqKey="Jessner W" first="Wolfgang" last="Jessner">Wolfgang Jessner</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25482330</idno><idno type="pmid">25482330</idno><idno type="doi">10.1016/S1473-3099(14)71002-3</idno><idno type="wicri:Area/PubMed/Corpus">003121</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003121</idno><idno type="wicri:Area/PubMed/Curation">003025</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003025</idno><idno type="wicri:Area/PubMed/Checkpoint">003025</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003025</idno><idno type="wicri:Area/Ncbi/Merge">002079</idno><idno type="wicri:Area/Ncbi/Curation">002079</idno><idno type="wicri:Area/Ncbi/Checkpoint">002079</idno><idno type="wicri:Area/Main/Merge">002834</idno><idno type="wicri:Area/Main/Curation">002834</idno><idno type="wicri:Area/Main/Exploration">002834</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.</title><author><name sortKey="Reddy, K Rajender" sort="Reddy, K Rajender" uniqKey="Reddy K" first="K Rajender" last="Reddy">K Rajender Reddy</name><affiliation wicri:level="2"><nlm:affiliation>Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: rajender.reddy@uphs.upenn.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, JW Goethe University Hospital, Frankfurt, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medicine, JW Goethe University Hospital, Frankfurt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name><affiliation wicri:level="3"><nlm:affiliation>Hospices Civils de Lyon, INSERM U1052, Lyon 1 University, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospices Civils de Lyon, INSERM U1052, Lyon 1 University, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Weiland, Ola" sort="Weiland, Ola" uniqKey="Weiland O" first="Ola" last="Weiland">Ola Weiland</name><affiliation wicri:level="3"><nlm:affiliation>Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Horban, Andrzej" sort="Horban, Andrzej" uniqKey="Horban A" first="Andrzej" last="Horban">Andrzej Horban</name><affiliation wicri:level="1"><nlm:affiliation>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Stanciu, Carol" sort="Stanciu, Carol" uniqKey="Stanciu C" first="Carol" last="Stanciu">Carol Stanciu</name><affiliation wicri:level="1"><nlm:affiliation>Gastromedica Clinic, University Hospital St Spiridon, Iasi, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Gastromedica Clinic, University Hospital St Spiridon, Iasi</wicri:regionArea><wicri:noRegion>Iasi</wicri:noRegion></affiliation></author><author><name sortKey="Villamil, Federico Guillermo" sort="Villamil, Federico Guillermo" uniqKey="Villamil F" first="Federico Guillermo" last="Villamil">Federico Guillermo Villamil</name><affiliation wicri:level="1"><nlm:affiliation>CIPREC, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>CIPREC, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Andreone, Pietro" sort="Andreone, Pietro" uniqKey="Andreone P" first="Pietro" last="Andreone">Pietro Andreone</name><affiliation wicri:level="1"><nlm:affiliation>Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna and AOU Policlinico Sant'Orsola-Malpighi, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna and AOU Policlinico Sant'Orsola-Malpighi, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="George, Jacob" sort="George, Jacob" uniqKey="George J" first="Jacob" last="George">Jacob George</name><affiliation wicri:level="1"><nlm:affiliation>Storr Liver Unit, Westmead Hospital and Westmead Millennium Institute, Westmead, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Storr Liver Unit, Westmead Hospital and Westmead Millennium Institute, Westmead, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Dammers, Elisabeth" sort="Dammers, Elisabeth" uniqKey="Dammers E" first="Elisabeth" last="Dammers">Elisabeth Dammers</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Fu, Min" sort="Fu, Min" uniqKey="Fu M" first="Min" last="Fu">Min Fu</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research and Development, Spring House, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research and Development, Spring House, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Kurland, Darryl" sort="Kurland, Darryl" uniqKey="Kurland D" first="Darryl" last="Kurland">Darryl Kurland</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research and Development, Titusville, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research and Development, Titusville, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Ouwerkerk Mahadevan, Sivi" sort="Ouwerkerk Mahadevan, Sivi" uniqKey="Ouwerkerk Mahadevan S" first="Sivi" last="Ouwerkerk-Mahadevan">Sivi Ouwerkerk-Mahadevan</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Research and Development, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Research and Development, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Verbinnen, Thierry" sort="Verbinnen, Thierry" uniqKey="Verbinnen T" first="Thierry" last="Verbinnen">Thierry Verbinnen</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Scott, Jane" sort="Scott, Jane" uniqKey="Scott J" first="Jane" last="Scott">Jane Scott</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Global Services, High Wycombe, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Janssen Global Services, High Wycombe</wicri:regionArea><wicri:noRegion>High Wycombe</wicri:noRegion></affiliation></author><author><name sortKey="Jessner, Wolfgang" sort="Jessner, Wolfgang" uniqKey="Jessner W" first="Wolfgang" last="Jessner">Wolfgang Jessner</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Lancet. Infectious diseases</title><idno type="eISSN">1474-4457</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antiviral Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Genotype</term><term>Hepacivirus (classification)</term><term>Hepacivirus (genetics)</term><term>Hepacivirus (isolation & purification)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Hepatitis C, Chronic (virology)</term><term>Heterocyclic Compounds, 3-Ring (therapeutic use)</term><term>Humans</term><term>Interferon-alpha (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Oligopeptides (therapeutic use)</term><term>Placebos (administration & dosage)</term><term>Polyethylene Glycols (therapeutic use)</term><term>Recombinant Proteins (therapeutic use)</term><term>Ribavirin (therapeutic use)</term><term>Simeprevir</term><term>Sulfonamides (therapeutic use)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (usage thérapeutique)</term><term>Composés hétérocycliques 3 noyaux (usage thérapeutique)</term><term>Femelle</term><term>Génotype</term><term>Hepacivirus ()</term><term>Hepacivirus (génétique)</term><term>Hepacivirus (isolement et purification)</term><term>Humains</term><term>Hépatite C chronique (traitement médicamenteux)</term><term>Hépatite C chronique (virologie)</term><term>Interféron alpha (usage thérapeutique)</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Oligopeptides (usage thérapeutique)</term><term>Placebo (administration et posologie)</term><term>Polyéthylène glycols (usage thérapeutique)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Ribavirine (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Siméprévir</term><term>Sujet âgé</term><term>Sulfonamides (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Placebos</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Heterocyclic Compounds, 3-Ring</term><term>Interferon-alpha</term><term>Oligopeptides</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Placebo</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Composés hétérocycliques 3 noyaux</term><term>Interféron alpha</term><term>Oligopeptides</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Simeprevir</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Génotype</term><term>Hepacivirus</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Siméprévir</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We did a phase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and compensated liver disease that related to the standard of care for these patients at the time this study was initiated. We investigated whether simeprevir is non-inferior in terms of efficacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Argentine</li><li>Australie</li><li>Belgique</li><li>France</li><li>Italie</li><li>Pologne</li><li>Roumanie</li><li>Royaume-Uni</li><li>Suède</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>District de Darmstadt</li><li>Hesse (Land)</li><li>New Jersey</li><li>Pennsylvanie</li><li>Rhône-Alpes</li><li>Svealand</li></region><settlement><li>Francfort-sur-le-Main</li><li>Lyon</li><li>Stockholm</li></settlement></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Reddy, K Rajender" sort="Reddy, K Rajender" uniqKey="Reddy K" first="K Rajender" last="Reddy">K Rajender Reddy</name></region><name sortKey="Fu, Min" sort="Fu, Min" uniqKey="Fu M" first="Min" last="Fu">Min Fu</name><name sortKey="Kurland, Darryl" sort="Kurland, Darryl" uniqKey="Kurland D" first="Darryl" last="Kurland">Darryl Kurland</name></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name></region></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name></region></country><country name="Suède"><region name="Svealand"><name sortKey="Weiland, Ola" sort="Weiland, Ola" uniqKey="Weiland O" first="Ola" last="Weiland">Ola Weiland</name></region></country><country name="Pologne"><noRegion><name sortKey="Horban, Andrzej" sort="Horban, Andrzej" uniqKey="Horban A" first="Andrzej" last="Horban">Andrzej Horban</name></noRegion></country><country name="Roumanie"><noRegion><name sortKey="Stanciu, Carol" sort="Stanciu, Carol" uniqKey="Stanciu C" first="Carol" last="Stanciu">Carol Stanciu</name></noRegion></country><country name="Argentine"><noRegion><name sortKey="Villamil, Federico Guillermo" sort="Villamil, Federico Guillermo" uniqKey="Villamil F" first="Federico Guillermo" last="Villamil">Federico Guillermo Villamil</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Andreone, Pietro" sort="Andreone, Pietro" uniqKey="Andreone P" first="Pietro" last="Andreone">Pietro Andreone</name></noRegion></country><country name="Australie"><noRegion><name sortKey="George, Jacob" sort="George, Jacob" uniqKey="George J" first="Jacob" last="George">Jacob George</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Dammers, Elisabeth" sort="Dammers, Elisabeth" uniqKey="Dammers E" first="Elisabeth" last="Dammers">Elisabeth Dammers</name></noRegion><name sortKey="Jessner, Wolfgang" sort="Jessner, Wolfgang" uniqKey="Jessner W" first="Wolfgang" last="Jessner">Wolfgang Jessner</name><name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name><name sortKey="Ouwerkerk Mahadevan, Sivi" sort="Ouwerkerk Mahadevan, Sivi" uniqKey="Ouwerkerk Mahadevan S" first="Sivi" last="Ouwerkerk-Mahadevan">Sivi Ouwerkerk-Mahadevan</name><name sortKey="Verbinnen, Thierry" sort="Verbinnen, Thierry" uniqKey="Verbinnen T" first="Thierry" last="Verbinnen">Thierry Verbinnen</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Scott, Jane" sort="Scott, Jane" uniqKey="Scott J" first="Jane" last="Scott">Jane Scott</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002834 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002834 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25482330
|texte= Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25482330" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |